**Core Concept**
Cisatracurium is a stereoisomer of atracurium, a non-depolarizing neuromuscular blocking agent. The difference between these two compounds is crucial for their clinical use, particularly in patients with histamine release reactions.

**Why the Correct Answer is Right**
Cisatracurium is better than atracurium due to its reduced propensity for histamine release. Atracurium is known to cause histamine release, which can lead to adverse effects such as hypotension, tachycardia, and bronchospasm. In contrast, cisatracurium has a lower incidence of histamine release, making it a safer option for patients with a history of anaphylaxis or those at risk for cardiovascular instability. This is because cisatracurium undergoes Hofmann elimination, a chemical process that does not involve histamine release, unlike the ester hydrolysis of atracurium.

**Why Each Wrong Option is Incorrect**
**Option B:** Cisatracurium and atracurium have similar half-lives, ranging from 20 to 30 minutes. Therefore, this option is incorrect because the half-life is not a significant difference between the two agents.
**Option C:** The dose of cisatracurium is not significantly lower than that of atracurium. In fact, the dosing requirements are similar for both agents, making this option incorrect.
**Option D:** The cost of cisatracurium is not necessarily lower than that of atracurium. While cost can be a factor in medication selection, it is not the primary reason for choosing cisatracurium over atracurium.

**Clinical Pearl / High-Yield Fact**
When choosing a neuromuscular blocking agent, consider the patient's risk factors for histamine release, such as a history of anaphylaxis or cardiovascular instability. Cisatracurium is a safer option in these cases due to its reduced propensity for histamine release.

**✓ Correct Answer: A. Less histamine release**